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Abstract
Objectives: Total pancreatectomy (TP) is associated with significant morbidity and mortality. The sever-
ity of postoperative diabetes and existence of ‘brittle diabetes’ are unclear. This study sought to identify
quality of life (QoL) and diabetes-specific outcomes after TP.
Methods: Patients who underwent TP were matched for age, sex and duration of diabetes with patients
with type 1 diabetes. General QoL was assessed using the European Organization for Research and
Treatment of Cancer (EORTC) core quality of life questionnaire QLQ-C30 and the PAN26 tool. Diabetes-
specific outcomes were assessed using the Problem Areas in Diabetes (PAID) tool and an assessment of
diabetes-specific complications and outcomes.
Results: A total of 123 patients underwent TP; 88 died (none of diabetic complications) and two were
lost to follow-up. Of the remaining 33 patients, 28 returned questionnaires. Fourteen general and
pancreas-specific QoL measurements were all significantly worse amongst the TP cohort (QLQ-C30 +
PAN26). However, when diabetes-specific outcomes were compared using the PAID tool, only one of 20
was significantly worse. HbA1c values were comparable (P = 0.299), as were diabetes-related compli-
cations such as hypoglycaemic attacks and organ dysfunction.
Conclusions: Total pancreatectomy is associated with impaired QoL on general measures compared
with that in type 1 diabetes patients. Importantly, however, there was almost no significant difference in
diabetes-specific outcomes as assessed by a diabetes-specific questionnaire, or in diabetes control. This
study does not support the existence of ‘brittle diabetes’ after TP.
Received 20 September 2013; accepted 30 October 2013
Correspondence
Keith J. Roberts, Department of Hepatopancreatobiliary Surgery, Room 41e, Third Floor, Nuffield House,
University Hospital Birmingham, Edgbaston B15 2TH, UK. Tel: + 44 7801 658505. Fax: + 44 121 414 1833.
E-mail: keith.roberts@uhb.nhs.uk
Introduction
Total pancreatectomy (TP) is an uncommon operation, although
the present indications for this procedure may bring about an
increase in its use. One of the main barriers to performing TP is
the morbidity inherently related to the procedure. Of particular
relevance are concerns regarding postoperative diabetes, which
some authors believe is so severe that it warrants the designation
‘brittle diabetes’ in reference to its erratic blood sugar levels and
the difficulty of controlling them.1,2
Total pancreatectomy was initially performed in 19443 and
gained popularity in the 1970s as a result of concerns related to the
occurrence of pancreatic fistula following partial pancreatectomy,
multicentric carcinoma and potential benefits to be derived from
extended lymphadenectomy.4–6 However, because it is now recog-
nized that local recurrence after partial pancreatic resection does
not reflect multicentric disease, and because partial pancreatec-
tomy is associated with improved survival and morbidity over TP,
the latter is now seldom performed.7 To compound the high rates
of perioperative morbidity and mortality previously associated
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with TP,8–10 the metabolic consequences of exocrine and endo-
crine insufficiency were severe and were compromised by the
medical therapy available at the time.1,11 However, the treatment of
pancreatic exocrine and endocrine insufficiency is presently well
understood and medical management has improved.11–13
Thus there remains a role for TP in selected circumstances. It is
likely that its use will increase in some, if not all, pancreatic centres
as understanding of pancreatic disease and of what is considered
achievable by surgical means evolves. Firstly, intraductal papillary
mucinous neoplasia (IPMN) has been identified and with it the
recognition that main duct type can be associated with malignant
transformation throughout the pancreas gland.14–16 Other clinical
scenarios in which TP is required include multifocal disease such
as renal cell metastasis.17,18 The procedure can also be used as a
strategy of debridement and sepsis control following serious
complications of partial pancreatectomy.18 Post-pancreatectomy
haemorrhage is a life-threatening complication following pancre-
atic surgery and almost exclusively occurs in the setting of post-
operative pancreatic fistula (POPF).19 Arterial resection during
pancreatectomy is uncommon, but one strategy for decreasing
perioperative morbidity is to perform TP in this setting, thus
avoiding the dreaded complication of POPF in the presence of an
arterial anastomosis.20
The decision to undertake TP is made in the knowledge of the
associated risks for morbidity and mortality. In some clinical sce-
narios, such as in completion pancreatectomy in the setting of
complicated POPF, in IPMN without multifocal carcinoma and in
the context of a decision on whether to perform arterial resection,
there are alternative treatment options. Thus the decision to
undertake TP may be affected by an understanding of the patient’s
post-pancreatectomy state. One of the most important aspects, if
not the most important, is the severity of post-TP diabetes.
Thus the aim of this study was to perform an analysis of quality
of life (QoL) and diabetes-specific outcomes in patients submitted
to TP in order to clarify the severity of post-TP diabetes and to
verify the existence of the entity described as ‘brittle diabetes’.
Materials and methods
Patients who had undergone TP at the University of Hospitals
Birmingham National Health Service (NHS) Trust were identified
from a prospectively maintained database. Both patients who had
undergone planned TP and those with a subsequent completion
pancreatectomy were included. The study period ran from 1
January 1988 to 1 June 2012; this end date permitted a minimum
length of follow-up of 12 months.
Study patients were matched with a cohort of patients with type
1 diabetes in an attempt to identify whether the diabetic state
associated with TP is indeed worse than or comparable with that
in patients with type 1 diabetes. These patients were selected as the
ideal control group because their diabetic state and treatment
options are clearly understood, and the disease is common. Thus
this group provides a natural comparison sample with which to
compare diabetes-related outcomes and complications. Patients
with type 2 diabetes were excluded, even if they were insulin-
dependent, because this disease state reflects peripheral insulin
resistance. Patients with type 1 diabetes were identified from a
separate prospectively maintained database. Patients were
matched on duration of insulin dependence (within 3 years of
each other), by age (within 5 years of each other) and sex. For
most patients in the TP cohort, the duration of diabetes corre-
sponded to time since TP, although some patients had pre-existing
insulin-treated diabetes (i.e. those with chronic pancreatitis). In
this scenario, the duration of diabetes was taken from the time of
diagnosis of insulin dependence.
Generic QoL was assessed using the European Organization for
the Research and Treatment of Cancer (EORTC) core quality of
life questionnaire QLQ-C3021 (Version 3, with permission from
the EORTC data centre). Scores were analysed according to the
scoring manual provided by the EORTC. The additional EORTC
pancreatic model, PAN26, which has been validated in both
chronic pancreatitis and malignant disease settings, was also used
with the agreement of the EORTC.
A diabetes-specific questionnaire using the Problem Areas in
Diabetes (PAID) scale was used to assess diabetes-specific out-
comes.22,23 HbA1c levels are reported in mmol/mol.
A final set of specific questions was constructed to assess for
evidence of diabetes control and end organ damage related to
diabetes.
All patients were sent a postal request with copies of these
questionnaires. Additional information relating to the medical
outcomes of diabetes, such as HbA1c levels, were sought from
general practitioners and hospital records. Any non-responders
were re-sent the questionnaire.
The related-samples Wilcoxon signed rank and McNemar
chi-squared tests were used to compare outcomes from matched
subjects. Bonferroni correction was performed in the analyses of
multiple responses to the QLQ-C30, PAN26 and PAID question-
naires. Non-matched data were compared using the Mann–
Whitney and chi-squared tests. Data are expressed as the median
[interquartile range (IQR)]. All analyses were performed using
IBM spss Statistics Version 21 (IBM Corp., Armonk, NY, USA).
A medical statistician provided advice on data analysis and
interpretation.
Results
A total of 123 patients underwent TP over the study period of 24
years.There was an increase in the number of procedures over time:
in the first, second, third and fourth quartiles of the study period,
TP was performed in 14, 23, 44 and 42 patients, respectively.
The setting of TP (i.e. as an elective planned procedure or as an
emergency completion pancreatectomy) and outcomes at last
follow-up are summarized in Fig 1.
A total of 88 patients (71.5%) had died and two were lost to
follow-up. Causes of death are summarized in Fig 1; importantly,
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no patient died as a direct result of diabetes-related complications
such as hypoglycaemia or ketoacidosis. One patient died with a
history of diabetic nephropathy, below-knee amputation for
peripheral vascular disease and general frailty. The median sur-
vival of the whole cohort was 2.0 years (IQR: 0.3–5.6 years) and
median potential follow-up was 9.9 years (IQR: 6.1–14.6 years).
Study group
Of the remaining 33 patients, 28 were alive and responded to the
questionnaire. These included 16 men. The median age of
responders was 63 years. Of the TP procedures, 25 had been
planned and three were completion pancreatectomies in the
setting of POPF and sepsis. Nine procedures were performed for
chronic pancreatitis, five for IPMN, three for renal cancer metas-
tases, three for multifocal neuroendocrine tumours, two for pan-
creatic adenocarcinoma, one for necrotizing pancreatitis, one for
solid pseudopapillary tumour and one for microcystic adenoma.
Matched analysis
Predominately because of age differences between patients in the
two databases [young patients predominated in the control type 1
diabetes database (median age: 42 years; IQR: 29–54 years),
whereas elderly patients predominated in the TP database
(median age: 63 years; IQR: 47–69 years)], it was possible to match
23 patients. A comparison of matching variables between the
control and TP cohorts, respectively, showed no differences in
median age [53.0 years (IQR: 46.5–60.5 years) versus 58.0 years
(IQR: 45.5–68.0 years); P = 0.169], median duration of diabetes
[13.4 years (IQR: 5.9–16.9 years) versus 10.3 years (IQR: 7.6–12.4
years); P = 0.589] or male/female sex ratios (14/9 versus 14/9; P =
1). The median time since TP was 8.7 years (IQR: 5.6–11.6 years).
The median age of the remaining five unmatched TP patients
was 69.0 years (IQR: 68.0–71.0 years). Their median duration of
diabetes was short at 4.0 years (IQR: 3.5–5.7 years). All demo-
graphic variables, outcomes reported in the QLQ-C30, PAN26
and PAID questionnaires and assessments of diabetes-specific
outcomes were compared between these five unmatched patients
and the 23 matched patients. The only variable that differed sig-
nificantly between these two groups was age (P = 0.041, Mann–
Whitney U-test; remaining data not shown).
Quality of life outcomes
Quality of life outcomes as assessed by the QLQ-C30 were lower in
the TP cohort than in the control cohort with reference to physical
status, working ability, cognitive functioning, social functioning,
fatigue, nausea and vomiting, and dyspnoea (Table 1). The differ-
ence between the control and TP cohorts in the score of patients
reporting steatorrhoea almost reached significance (P = 0.050).
The TP cohort also reported worse pancreas-specific pain symp-
toms, dietary restriction, hepatic symptoms, bloating, bad-tasting
food, flatulence, weakness and treatment side-effects compared
with the control diabetes cohort as assessed by the PAN26 tool
(Table 1). After Bonferroni correction, only physical status, fatigue
and bloating remained significant.
Total pancreatectomy (n = 123)
Elective (n = 88)
Recurrent cancer (n = 47)
Postop sepsis/complications (n = 30)
Unknown cause of death (n = 3)
Unrelated malignancy (n = 2)
Pulmonary embolism (n = 1)
Suicide (n = 1)
Pneumonia (n = 1)
Frailty with evidence of diabetic
end organ damage (n = 1)
Intracerebral haemorrhage/cerebrovascular accident (n = 2)
Emergency completion after PP with
complications (n = 35)
Elective completion after previous PP (n = 8)
Lost to follow-up (n = 2)Dead (n = 88) Alive (n = 33)
Figure 1 Summary of data in the entire cohort of patients undergoing total pancreatectomy (TP) and outcomes at last follow-up. No
patient died as a direct result of diabetes-related complications; one patient died with evidence of diabetic organ damage. PP, partial
pancreatectomy
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Table 1 Responses of type 1 diabetes control patients and diabetes patients submitted to total pancreatectomy (TP) to general quality of life
measures as assessed by the European Organization for the Research and Treatment of Cancer (EORTC) core quality of life questionnaire
QLQ-C30 and pancreas-specific supplementary module PAN26
Item Cohort score, median (IQR) P-value
Control group TP group
(n = 23) (n = 23)
QLQ-C30 functional scales
Physical status 100 (86.6–100) 66.7 (43.3–86.6) <0.001b
Working ability 100 (91.7–100) 66.7 (41.7–83.3) 0.013a
Cognitive functioning 100 (83.3–100) 66.7 (33.3–91.7) 0.009a
Emotional functioning 83.3 (66.7–95.8) 66.7 (50.0–95.8) 0.204
Social functioning 100 (66.7–100) 66.7 (33.3–100) 0.019a
Global quality of life 66.7 (50.0–83.3) 58.3 (29.2–70.8) 0.109
QLQ-C30 symptom scales
Fatigue 11.1 (0–27.8) 44.4 (33.3–72.2) 0.003b
Nausea and vomiting 0 (0–0) 0 (0–16.7) 0.013a
Pain 0 (0–25) 16.7 (0–50.0) 0.191
Dyspnoea 0 (0–16.7) 0 (0–33.3) 0.336
Insomnia 33.3 (0–33.3) 66.7 (33.3–100) 0.008a
Appetite loss 0 (0–33.3) 0 (0–66.7) 0.219
Constipation 0 (0–0) 0 (0–33.3) 0.959
Diarrhoea 0 (0–0) 0 (0–33.3) 0.070
Financial difficulties 0 (0–16.7) 33.3 (0–50.0) 0.147
PAN26 symptom scales
Pancreas-specific pain 8.3 (4.2–26.7) 33.3 (22.5–62.5) 0.011a
Diet restriction 16.7 (0–33.3) 50 (25.0–66.7) 0.007a
Jaundice and pruritus 0 (0–16.7) 16.7 (0–33.3) 0.006a
Steatorrhoea 16.7 (0–33.3) 50 (33.3–66.7) 0.05
Poor body image 16.7 (0–50.0) 16.7 (0–58.3) 0.716
Sexual dysfunction 33.3 (0–66.7) 33.3 (0–100) 0.322
Dissatisfaction with health care 66.7 (25–83.3) 66.7 (41.7–100) 0.392
Bloating 0 (0–0) 33.3 (0–66.7) 0.001b
Bad tasting food 0 (0–0) 0 (0–33.3) 0.003b
Indigestion 0 (0–0) 0 (0–33.3) 0.103
Flatulence 0 (0–33.3) 33.3 (0–83.3) 0.006a
Difficulty gaining weight 0 (0–0) 0 (0–16.7) 0.327
Weakness 0 (0–33.3) 33.3 (16.7–66.7) 0.016a
Dry mouth 0 (0–33.3) 66.7 (16.7–66.7) 0.008a
Treatment side-effects 0 (0–33.3) 33.3 (0–50.0) 0.020a
Worry about health care in the future 33.3 (16.7–66.7) 33.3 (33.3–66.7) 0.500
Difficulty in planning future events 0 (0–16.7) 0 (0–33.3) 0.264
On the functional scales, a higher value represents higher quality of life; on the symptom scales, a higher value represents worse symptoms (range:
0–100).
aSignificance at P < 0.05, Wilcoxon signed ranks test.
bSignificance with Bonferroni correction (P < 0.0033 for QLQ-C30 responses and P < 0.0029 for PAN26 responses).
IQR, interquartile range.
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Diabetes-specific outcomes
There was almost no significant difference between the two
cohorts. Scores on the PAID showed that the TP cohort reported
statistically significantly more concern regarding hypoglycaemic
reactions, although none of the other 19 questions elicited a sig-
nificant difference in responses (Table 2). However, this difference
became non-significant after Bonferroni correction.
There was no significant difference between the two groups in
numbers of patients who had experienced hypoglycaemic attacks,
hospital admissions or diabetic ketoacidotic episodes, or in the
numbers of patients with documented evidence of peripheral vas-
cular disease, cardiovascular disease, nephropathy, neuropathy or
retinopathy. Median HbA1c was comparable between the control
and TP groups (P = 0.299). Table 3 summarizes these data.
Discussion
This study reports general QoL and diabetes-specific outcomes in
patients submitted to TP compared with those in matched
patients with type 1 diabetes with the specific aim of reviewing the
diabetic state post-TP. Total pancreatectomy is associated with
severe metabolic derangement1,8–11 and some authors consider the
associated diabetic state, so-called ‘brittle diabetes’, to be particu-
larly severe.1,2 The present study predominately used patient-
reported outcomes obtained through validated questionnaires,
together with objective evidence assessing the management of
diabetes, such as occurrences of hypoglycaemic episodes and
HbA1c values. The main findings concerned the significantly
worse reported outcomes amongst the TP cohort, but these were
centred around general QoL and non-diabetes outcomes.
However, just one of 20 reported outcomes as assessed by the
diabetes-specific PAID questionnaire showed a significant differ-
ence between the groups (although this significance was lost after
Bonferroni correction) and, furthermore, no significant differ-
ences emerged in the incidence of diabetic complications or
glucose control as assessed by HbA1c levels. One conclusion of
this study is therefore that the post-TP diabetic state is similar to
that in patients with type 1 diabetes and that there is no objective
or subjective evidence to demonstrate that the post-TP diabetic
state is more severe. The lack of any significant difference in
organ-specific complications (such as nephropathy) may relate to
the relatively short duration of the median follow-up of 8.7 years.
Table 2 Comparisons of scores on the Problem Areas in Diabetes (PAID) scale in type 1 diabetes control patients and diabetes patients
submitted to total pancreatectomy (TP)
Item Cohort score, median (IQR) P-value
Control group TP group
(n = 23) (n = 23)
Not having clear and concrete goals for your diabetes care? 0 (0–1) 1 (0–2) 0.113
Feeling discouraged with your diabetes treatment plan? 0 (0–1) 0 (0–1.5) 0.501
Feeling scared when you think about living with diabetes? 1 (0–2) 1 (0–3) 0.440
Uncomfortable social situations related to your diabetes (e.g. people telling you what to eat)? 0 (0–1) 1 (0–2) 0.402
Feelings of deprivation regarding food and meals? 1 (0–1) 1 (0–2) 0.204
Feeling depressed when you think about living with diabetes? 1 (0–2) 1 (0–2.5) 0.744
Not knowing if your mood or feelings are related to your diabetes? 1 (0–2) 1 (0.5–2) 0.220
Feeling overwhelmed by your diabetes? 1 (0–2) 1 (0–2) 0.698
Worrying about low blood sugar reactions? 1 (1–2) 2 (1–3) 0.014a
Feeling angry when you think about living with diabetes? 1 (0–2) 1 (0–2.5) 0.299
Feeling constantly concerned about food and eating? 1 (0–1) 2 (0–3) 0.141
Worrying about the future and the possibility of serious complications? 2 (1–2.5) 3 (0–4) 0.127
Feelings of guilt or anxiety when you get off track with your diabetes management? 1 (1–2.5) 1 (0–3) 0.690
Not ‘accepting’ your diabetes? 0 (0–1) 0 (0–1) 1.000
Feeling unsatisfied with your diabetes physician? 0 (0–0) 0 (0–0) 0.461
Feeling that diabetes is taking up too much of your mental and physical energy every day? 1 (0–2) 2 (0–3) 0.086
Feeling alone with your diabetes? 0 (0–1) 0 (0–1.5) 0.543
Feeling that your friends and family are not supportive of your management efforts? 0 (0–1) 0 (0–1) 0.749
Coping with the complications of diabetes? 1 (0–2) 2 (0–3) 0.084
Feeling ‘burned’ out by the constant effort needed to manage diabetes? 1 (0–2) 2 (0–3) 0.338
Scores vary from 0, which represents ‘not a problem’, to 4, representing a ‘serious problem’.
aSignificance at P < 0.05, Wilcoxon signed ranks test.
IQR, interquartile range.
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However, the similarities between the groups in HbA1c levels and
episodes of hypoglycaemia or ketoacidosis provide no evidence
from short-term outcomes to support the suggestion that diabetes
control is worse in TP patients. Longitudinal follow-up would be
required to confidently compare organ-specific diabetes-related
complications.
It is not surprising that general QoL outcomes were worse in
the TP cohort because the majority of these patients underwent
TP for either malignant disease or pancreatitis. Both of these
conditions are known to adversely affect QoL measurements.24–26
There is evidence that TP is related to a worse QoL than partial
pancreatic resection. In a matched analysis of QoL outcomes
assessed by the QLQ-C30 tool in patients submitted to TP and
pylorus-preserving pancreatoduodenectomy, respectively, a worse
functional scale, role function, social function and symptom scale
were observed in the TP cohort.18
Further studies addressing QoL and outcomes following TP are
required because information in this area is scant and there is
growing re-interest in TP as an operative strategy. It is likely that
surgeons will consider TP in more patients as a result of the
recognition of diffuse parenchymal diseases such as IPMN,14–16
multifocal metastases17,18 and chronic pancreatitis.27–29 A further
strategic use of TP is in the emergency setting as a way of control-
ling sepsis in a small proportion of patients with POPF after
partial pancreatectomy.18 Hence, understanding of the postopera-
tive outcomes following TP is important in order to allow patients
and clinicians to make informed decisions on whether or not to
proceed with TP. The few other studies to assess QoL after TP have
tended to focus upon general outcomes, although there is evi-
dence to support the observation of this study that post-TP dia-
betes may not be as severe as previously thought.1,2 The Heidelberg
group reported a mean HbA1c of 7.8% in a cohort of TP patients,
among whom no life-threatening complications attributable to
diabetes occurred.18 Diabetes control in TP patients at the present
study institution has been previously reviewed in a matched com-
parison with diabetes patient controls. Median HbA1c was found
to be comparable between the TP and control groups (8.2% and
8.1%, respectively).30 However, no formal QoL or subjective dia-
betes assessment was performed. In an observational study of
Italian TP patients, diabetes control was summarized as good:
there was a low rate of readmissions for diabetes, no deaths attrib-
utable to diabetes and median HbA1c was near normal at 8%.31 In
a non-matched comparison of TP patients with non-surgical dia-
betes patient controls, Billings et al. found no difference in out-
comes reported using the diabetes-specific Audit of Diabetes
Dependent QoL tool.32 They did, however, observe three late post-
operative deaths caused by hypoglycaemia. Deaths attributable to
complications of diabetes (hypoglycaemia, n = 1; ketoacidosis, n =
1) were also recently reported amongst 56 TP patients.33 In the
present study, only one patient died with evidence of end organ
damage related to diabetes. No patient died as a direct result of
hypoglycaemia or ketoacidosis. One potential weakness of the
present study is the median duration of follow-up as this limits an
assessment of the longterm effects of diabetes. This duration,
however, is longer than follow-up in other studies reviewing QoL
and diabetes-related complications after TP.18,31–33
A further weakness of the present study refers to its failure to
successfully match a small proportion of the TP patients included.
Table 3 Comparison of diabetes-specific physiological outcome measures in type 1 diabetes control patients and diabetes patients
submitted to total pancreatectomy (TP)
Complication/outcome Cohort P-value
Control group TP group
(n = 23) (n = 23)
Hypoglycaemic attack in the past month, n 12 14 0.754
Hypoglycaemia requiring hospital admission in past year, n 0 5 0.5
Previous episode of diabetic ketoacidosis, n 2 0 0.5
Peripheral vascular disease, n 0 1 1
Cardiovascular disease, n 12 9 0.508
Peripheral neuropathy, n 3 5 0.727
Autonomic neuropathy, n 1 0 1
Erectile dysfunction, n 0 0 1
Retinopathy, n 5 3 0.688
Nephropathy, n 1 1 1
Injection site complications, n 0 0 1
Has/under consideration for an insulin pump, n 2 0 0.5
HbA1c mmol/mol, median (IQR) 74.5 (58.75–91) 65 (56.25–80) 0.299a
McNemar's chi-squared test or aWilcoxon signed rank test.
IQR, interquartile range.
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Cross-analysis of the unmatched and matched TP patients,
however, suggests that outcomes in both groups were comparable
and that the only significant difference referred to age. It was this
variable that made matching impossible for these patients. Thus,
although these patients were not included in the matched analysis,
it seems that their reported outcomes were comparable with those
of the TP patients who were included in the matched analysis.
In conclusion, TP is associated with a significant risk for mor-
tality and impaired general QoL in comparison with those in
matched non-surgical controls with type 1 diabetes. However, the
diabetic state that occurs following TP does not appear to differ
significantly from that in the group of diabetes patient controls
when assessed according to diabetes-specific outcomes.
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